IL-33 blockade prevents exacerbations in a model of chronic airway inflammation by blunting persistent inflammation and remodeling
J. Allinne (Tarrytown, United States of America), W. Lim (Tarrytown, United States of America), G. Scott (Tarrytown, United States of America), C. Sandén (Lund, Sweden), J. Erjefält (Lund, Sweden), D. Birchard (Tarrytown, United States of America), L. Ben (Tarrytown, United States of America), A. Murphy (Tarrytown, United States of America), M. Sleeman (Tarrytown, United States of America), J. Orengo (Tarrytown, United States of America)
Source: International Congress 2019 – Advances in asthma pharmacology
Session: Advances in asthma pharmacology
Session type: Poster Discussion
Number: 3876
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Allinne (Tarrytown, United States of America), W. Lim (Tarrytown, United States of America), G. Scott (Tarrytown, United States of America), C. Sandén (Lund, Sweden), J. Erjefält (Lund, Sweden), D. Birchard (Tarrytown, United States of America), L. Ben (Tarrytown, United States of America), A. Murphy (Tarrytown, United States of America), M. Sleeman (Tarrytown, United States of America), J. Orengo (Tarrytown, United States of America). IL-33 blockade prevents exacerbations in a model of chronic airway inflammation by blunting persistent inflammation and remodeling. 3876
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: